326 related articles for article (PubMed ID: 31244925)
1. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jan YJ; Yoon J; Chen JF; Teng PC; Yao N; Cheng S; Lozano A; Chu GCY; Chung H; Lu YT; Chen PJ; Wang JJ; Lee YT; Kim M; Zhu Y; Knudsen BS; Feng FY; Garraway IP; Gao AC; Chung LWK; Freeman MR; You S; Tseng HR; Posadas EM
Theranostics; 2019; 9(10):2812-2826. PubMed ID: 31244925
[No Abstract] [Full Text] [Related]
2. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI
Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
[TBL] [Abstract][Full Text] [Related]
4. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
5. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
[TBL] [Abstract][Full Text] [Related]
6. Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer.
Oeyen S; Liégeois V; De Laere B; Buys A; Strijbos M; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Dirix L
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):499-506. PubMed ID: 33230201
[TBL] [Abstract][Full Text] [Related]
7. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.
Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A
Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970
[No Abstract] [Full Text] [Related]
8. Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Groen L; Kloots I; Englert D; Seto K; Estafanos L; Smith P; Verhaegh GW; Mehra N; Schalken JA
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240349
[TBL] [Abstract][Full Text] [Related]
9. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.
Danila DC; Anand A; Schultz N; Heller G; Wan M; Sung CC; Dai C; Khanin R; Fleisher M; Lilja H; Scher HI
Eur Urol; 2014 Jun; 65(6):1191-7. PubMed ID: 23954088
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
[TBL] [Abstract][Full Text] [Related]
11. Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit.
Smith BN; Mishra R; Billet S; Placencio-Hickok VR; Kim M; Zhang L; Duong F; Madhav A; Scher K; Moldawer N; Oppenheim A; Angara B; You S; Tighiouart M; Posadas EM; Bhowmick NA
Mol Ther; 2023 Jan; 31(1):78-89. PubMed ID: 36045587
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting.
Lee YT; Sun N; Kim M; Wang JJ; Tran BV; Zhang RY; Qi D; Zhang C; Chen PJ; Sadeghi S; Finn RS; Saab S; Han SB; Busuttil RW; Pei R; Zhu Y; Tseng HR; You S; Yang JD; Agopian VG
Liver Transpl; 2022 Feb; 28(2):200-214. PubMed ID: 34664394
[TBL] [Abstract][Full Text] [Related]
13. Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.
Sperger JM; Helzer KT; Stahlfeld CN; Jiang D; Singh A; Kaufmann KR; Niles DJ; Heninger E; Rydzewski NR; Wang L; Wang L; Yang R; Ren Y; Engle JW; Huang P; Kyriakopoulos CE; Slovin SF; Soule HR; Zhao SG; Kohli M; Tagawa ST; Cai W; Dehm SM; Lang JM
Clin Cancer Res; 2023 Jun; 29(12):2324-2335. PubMed ID: 36939530
[TBL] [Abstract][Full Text] [Related]
14. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
[TBL] [Abstract][Full Text] [Related]
15. Detection of Androgen Receptor Variant 7 (
Hille C; Gorges TM; Riethdorf S; Mazel M; Steuber T; Amsberg GV; König F; Peine S; Alix-Panabières C; Pantel K
Cells; 2019 Sep; 8(9):. PubMed ID: 31514447
[TBL] [Abstract][Full Text] [Related]
16. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Jendrisak A; Wang Y; Lee J; Greene S; Krupa R; Lu D; Bamford P; Louw JE; Dugan L; Vargas HA; Fleisher M; Landers M; Heller G; Dittamore R
Cancer Res; 2017 Oct; 77(20):5687-5698. PubMed ID: 28819021
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
19. Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer.
Zavridou M; Smilkou S; Tserpeli V; Sfika A; Bournakis E; Strati A; Lianidou E
Clin Chem; 2022 Oct; 68(10):1323-1335. PubMed ID: 36093578
[TBL] [Abstract][Full Text] [Related]
20. Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
Barnett ES; Schultz N; Stopsack KH; Lam ET; Arfe A; Lee J; Zhao JL; Schonhoft JD; Carbone EA; Keegan NM; Wibmer A; Wang Y; Solit DB; Abida W; Wenstrup R; Scher HI
Eur Urol; 2023 Feb; 83(2):112-120. PubMed ID: 36123219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
